Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis

Merlini, 2011, Amyloidosis: pathogenesis and new therapeutic options, J Clin Oncol, 29, 1924, 10.1200/JCO.2010.32.2271 Palladini, 2015, A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis, Blood, 126, 612, 10.1182/blood-2015-01-620302 Sidana, 2018, Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains, Leukemia, 32, 729, 10.1038/leu.2017.286 Hamer, 1992, Amyloid cardiomyopathy in systemic non-hereditary amyloidosis: clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis, Eur Heart J, 13, 623, 10.1093/oxfordjournals.eurheartj.a060225 Zhao, 2016, Recent advances in the noninvasive strategies of cardiac amyloidosis, Heart Fail Rev, 21, 703, 10.1007/s10741-016-9580-5 Ridolfi, 1977, The conduction system in cardiac amyloidosis: clinical and pathologic features of 23 patients, Am J Med, 62, 677, 10.1016/0002-9343(77)90870-1 Volpi, 1986, Cardiac amyloidosis involving the conduction system and the aortocoronary neuroreceptors: clinicopathologic correlates, Chest, 90, 619, 10.1378/chest.90.4.619 Grogan, 2015, Natural history and therapy of AL cardiac amyloidosis, Heart Fail Rev, 20, 155, 10.1007/s10741-014-9464-5 Lin, 2013, Implantable cardioverter defibrillators in patients with cardiac amyloidosis, J Cardiovasc Electrophysiol, 24, 793, 10.1111/jce.12123 Goldsmith, 2009, Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring, Am J Cardiol, 104, 990, 10.1016/j.amjcard.2009.05.040 Sayed, 2015, A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis, Eur Heart J, 36, 1098, 10.1093/eurheartj/ehu506 Hess, 2004, Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients, Resuscitation, 60, 105, 10.1016/j.resuscitation.2003.08.007 Kristen, 2008, Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death, Heart Rhythm, 5, 235, 10.1016/j.hrthm.2007.10.016 Palladini, 2001, Holter monitoring in AL amyloidosis: prognostic implications, Pacing Clin Electrophysiol, 24, 1228, 10.1046/j.1460-9592.2001.01228.x Dubrey, 1997, Signal-averaged electrocardiography in patients with AL (primary) amyloidosis, Am Heart J, 134, 994, 10.1016/S0002-8703(97)70017-6 Dispenzieri, 2015, Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement, Mayo Clin Proc, 90, 1054, 10.1016/j.mayocp.2015.06.009 Gertz, 2016, Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment, Am J Hematol, 91, 947, 10.1002/ajh.24433 Gertz, 2013, Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis, Bone Marrow Transplant, 48, 557, 10.1038/bmt.2012.170 Dispenzieri, 2004, Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation, Blood, 104, 1881, 10.1182/blood-2004-01-0390 Kumar, 2012, Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements, J Clin Oncol, 30, 989, 10.1200/JCO.2011.38.5724 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Cox, 1972, Regression models and life-tables, J Royal Stat Soc Series B (Methodological), 34, 187, 10.1111/j.2517-6161.1972.tb00899.x Siontis, 2014, Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population, J Am Heart Assoc, 3, e001002, 10.1161/JAHA.114.001002 Olivotto, 2001, Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy, Circulation, 104, 2517, 10.1161/hc4601.097997 Longhi, 2015, Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role, Amyloid, 22, 147, 10.3109/13506129.2015.1028616 Arun, 2017, The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution, Bone Marrow Transplant, 52, 1349, 10.1038/bmt.2017.148 Gersh, 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary; a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 124, 2761, 10.1161/CIR.0b013e318223e230 Spirito, 1997, The management of hypertrophic cardiomyopathy, N Engl J Med, 336, 775, 10.1056/NEJM199703133361107 Maron, 2002, Hypertrophic cardiomyopathy: a systematic review, JAMA, 287, 1308, 10.1001/jama.287.10.1308 Maron, 2003, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 Monserrat, 2003, Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients, J Am Coll Cardiol, 42, 873, 10.1016/S0735-1097(03)00827-1 Muchtar, 2017, Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death, Blood, 129, 2111, 10.1182/blood-2016-11-751628